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Reduction of hexavalent chromium (Cr(VI)) to trivalent chromium (Cr(III)) in the stomach prior to
absorption is a well-recognized detoxiﬁcation process thought to limit the toxicity of ingested Cr(VI).
However, administration of high concentrations of Cr(VI) in drinking water cause mouse small intestinal
tumors, and quantitative measures of Cr(VI) reduction rate and capacity for rodent stomach contents are
needed for interspecies extrapolation using physiologically-based toxicokinetic (PBTK) models. Ex vivo
studies using stomach contents of rats and mice were conducted to quantify Cr(VI) reduction rate and
capacity for loading rates (1–400 mg Cr(VI) L1 stomach contents) in the range of recent bioassays. Cr(VI)
reduction was measured with speciated isotope dilution mass spectrometry to quantify dynamic Cr(VI)
and Cr(III) concentrations in stomach contents at select time points over 1 h. Cr(VI) reduction followed
mixed second-order kinetics, dependent upon concentrations of both Cr(VI) and the native reducing
agents. Approximately 16 mg Cr(VI)-equivalents of reducing capacity per L of fed stomach contents (con-
taining gastric secretions, saliva, water and food) was found for both species. The second-order rate con-
stants were 0.2 and 0.3 L mg1 h1 for mice and rats, respectively. These ﬁndings support that, at the
doses that caused cancer in the mouse small intestine (P20 mg Cr(VI) L1 in drinking water), the reduc-
ing capacity of stomach contents was likely exceeded. Thus, for extrapolation of target tissue dose in risk
assessment, PBTK models are necessary to account for competing kinetic rates including second order
capacity-limited reduction of Cr(VI) to Cr(III).
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2011a). However, based on estimates of mouse gastric reductive
capacity, which were developed from allometric scaling of body
weight to the three-fourths power (BW3=4) of human reduction
capacity measures, it has been suggested that the reductive capac-
ity was not exceeded in the NTP (2008) study mice, except perhaps
at the highest dose administered in females (Stout et al., 2009; Col-
lins et al., 2010; Stern, 2010).
Although Cr(VI) gastric reduction has been studied in humans
for several decades (Donaldson and Barreras, 1966; De Flora and
Boido, 1980; De Flora et al., 1987, 1997; Finley et al., 1997), the
gastric reduction kinetics of Cr(VI) in rodents has not been quanti-
ﬁed to date. Because Cr(VI) concentrations that caused tumors in
the NTP (2008) study were approximately 10000-fold higher than
typical drinking water exposures for humans, which are common
at 0.001–0.005 mg L1 (CDPH, 2011), rates and capacities of Cr(VI)
reduction in rodent stomach conditions are needed to inform
extrapolations across dose and species for risk assessment.
Rodents and humans differ in important ways in the structure
and function of the gastrointestinal tract (Kararli, 1995; de Zwart
et al., 1999; McConnell et al., 2008). The rodent stomach has two
deﬁned areas, a nonglandular forestomach and a glandular stomach
(de Zwart et al., 1999). Rodents with ad libitum feeding have food in
the stomach continuously (de Zwart et al., 1999) and do not expe-
rience signiﬁcant peaks in gastric acid production (Ito and Scho-
ﬁeld, 1974; Friis-Hansen et al., 1998). By contrast, humans have
greater acid production capacity with post-prandial peaks and far
more acidic gastric conditions while fasting (Kararli, 1995). Hence,
in humans, the gastric environment ismore variable than that of ro-
dents, andmay be further altered by pharmaceuticals, medical con-
ditions, and life-stage. Because of the aforementioned differences
between human and rodent stomach conditions, BW3=4 dose scaling,
which is typically used for interspecies extrapolation of dose in can-
cer risk assessment (U.S. EPA, 2011), may be highly uncertain, par-
ticularly for a portal of entry effect induced in the small intestine
(U.S. EPA, 2006; Thompson et al., 2008).
Reduction of Cr(VI) to Cr(III) in the stomach competes with
absorption and stomach emptying; thus both reduction rate and
capacity are important parameters for assessing dosimetry to the
intestine. In this context, the reduction rate refers to the rate at
which the Cr(VI) is reduced to Cr(III), and capacity refers to the to-
tal amount of Cr(VI) reduced per volume of stomach contents, gi-
ven inﬁnite time to react. The competing kinetic processes of
input to the stomach, emptying, absorption and reduction, are best
quantiﬁed using species-speciﬁc physiologically-based toxicoki-
netic (PBTK) models, which are the preferred method for interspe-
cies extrapolation in cancer risk assessment (U.S. EPA, 2005).
To assess key events in the carcinogenic mode of action (MOA),
90-d drinking water studies of Cr(VI) were conducted in F344/N
Fischer rats and B6C3F1 mice (Thompson et al., 2011b,2012). The
hypothesized MOA for intestinal carcinogenesis involves satura-
tion of the rodent stomach reductive capacity as the ﬁrst key event,
followed by absorption of Cr(VI) into the intestinal villi (Thompson
et al., 2011a). Ex vivo kinetic studies using the stomach contents of
rats and mice of the same strains used in the NTP (2008) bioassay
were conducted to simulate conditions of the NTP (2008) bioassay
and our 90-d drinking water studies, and to support development
of PBTK models.2. Methods and materials
2.1. Experimental design
Ex vivo studies were conducted to assess the rates and capaci-
ties for Cr(VI) reduction using stomach contents collected fromthe forestomach and glandular stomachs of Sprague–Dawley (SD)
rats, F344/N Fischer rats and B6C3F1 mice at Bioreclamation (Liv-
erpool, NY). Because the rodent stomach is being modeled as one
compartment in the rodent PBTK models that are under develop-
ment, contents from the entire stomach were used in this study.
Contents from fasted SD rats were collected for the pilot study to
assess method performance. A 12-h fasting period was applied
for the collection of ﬂuids from SD rats; however, food particles
were visible in these ﬂuids, and fasting for up to 24 h also yielded
ﬂuids that contained small amounts of food, most likely because of
food stored in the rodent forestomach. This indicated that food is
likely present in rodent stomach on a more or less continuous basis
under normal bioassay conditions. As a result, Cr(VI) reduction was
characterized in stomach contents from rodents under ad libitum
feeding conditions, which was considered to be representative of
conditions for the animals used in the Cr(VI) bioassays.
For the main phase of these studies, adult female B6C3F1 mice
and F344/N Fischer rats were fed irradiated NTP-2000 wafers
(Zeigler Brothers Inc.; Gardeners, PA), the same chow used in the
NTP (2008) study, ad libitum for at least 4 d prior to stomach con-
tent collection. All animals were euthanized with CO2 in the early
morning, following the dark period, and a total volume of 7 g fed
stomach contents was collected from each species using multiple
animals. Approximately 0.5–0.7 g of stomach contents was col-
lected from each rat, and approximately 0.15–0.2 g from each
mouse. It was the consistency of paste in both species. The fed
stomach contents were frozen immediately and shipped frozen
to Applied Speciation (Bothell, WA) on dry ice.
All samples were thawed before conducting each reduction
study; hence, an investigation was needed to determine the opti-
mal time of pre-heating for activation of stomach contents. Using
samples collected from SD rats fasted for 12 h, it was demonstrated
that stomach contents reached optimal reductive capacity follow-
ing approximately 60–90 min of heating at 37 C (Supplemental
Fig. 1). Hence, a pre-heating period of 60 min prior to addition of
Cr(VI) was used in all rate and capacity studies.
All experiments were conducted using stomach samples diluted
9:1 with 18 MX ultra-pure deionized (DI) water (Thermo Scien-
tiﬁc, Dubuque, IA) to achieve a consistency that would allow
homogenization and analysis. The pH of undiluted stomach con-
tent samples was measured using narrow range pH strips and
found to be approximately 4 for both species. Following dilution
with DI water at pH approximately 6, the pH of the diluted samples
was approximately 4.25 for rats and 4.25–4.5 for mice.
Following pre-heating, the diluted stomach sample was spiked
with Cr(VI) as SDD, which exists primarily as 52Cr, the naturally
abundant isotope. At speciﬁed times, ranging from 15 s to 60 min
after spiking with SDD, a sample (1–10 lL) of the spiked stomach
sample was collected and enriched rare isotopes of 53Cr(VI) and
50Cr(III) were added. All Cr enriched isotopes were purchased from
Applied Isotope Technologies (Pittsburgh, PA). Analysis of each iso-
tope was conducted thereafter using speciated isotope dilution
mass spectrometry (SIDMS) to determine the concentration of
Cr(VI) from the SDD spike that remained at the speciﬁed time.
Spiking with rare isotopes, followed by isotope-speciﬁc Cr(VI)
and Cr(III) analysis, allows for the determination of any valence
instability that might occur after spiking, which is corrected for
using this method (Huo et al., 1998; Rahman et al., 2005; Nagour-
ney et al., 2008).
2.2. Cr(VI) loading calculations
During the pilot study, it was determined that the reduction
kinetics of Cr(VI) in stomach ﬂuids at loading rates consistent with
the relevant bioassays occurs via a mixed second-order capacity-
limited, and concentration-dependent reaction (i.e., dependent
Table 1
Estimation of stomach loading in rats and mice to determine Cr(VI) spiking concentrations.
Cr(VI) DW concentrations
(mg L1)a
Estimated water intake
per bout (L)b
Cr(VI) intake per DW
bout (mg)c
Stomach contents at any one
time (fed state) (mL)d
Cr(VI) loading (mg Cr(VI) L1
stomach contents)e
Mouse
0.1 0.0002 0.00002 0.2 0.1
1.4 0.0002 0.00028 0.2 1.4
5.0 0.0002 0.0010 0.2 5.0
21 0.0002 0.0042 0.2 21
60 0.0002 0.012 0.2 60
180 0.0002 0.036 0.2 180
Rat
0.1 0.0007 0.00007 1 0.07
1.4 0.0007 0.00098 1 0.58
5.0 0.0007 0.0035 1 3.5
21 0.0007 0.015 1 15
60 0.0007 0.042 1 42
180 0.0007 0.13 1 130
a Cr(VI) concentrations converted from the SDD concentrations using molar mass percentage. Concentrations administered to animals tested in NTP (2008), Thompson
et al. (2011b), and Thompson et al. (2012).
b Water intake per bout for mice and rats were reported in Ho and Chin (1988), Glendinning and Smith (1994), and Spector and Smith (1984). In mice, water intake per
hourly bout was approximately 0.2 mL (Ho and Chin, 1988). In rats, water intake per bout was approximately 0.7 mL (Spector and Smith, 1984; Glendinning and Smith, 1994).
c Calculated Cr(VI) intake per drinking water bout (mg) from Cr(VI) drinking water concentrations (mg L1) and water intake per bout (L).
d In McConnell et al. (2008), fed state stomach contents of 0.2 mL and 1 mL were measured in mice and rats, respectively.
e Estimated Cr(VI) loading (mg Cr(VI) L1 stomach contents) calculated from Cr(VI) intake per drinking water bout (mg) and stomach contents at any given one time during
the fed state (mL) with a conversion factor of 1000.
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it was necessary to estimate the range of Cr(VI) stomach loading
concentrations of interest for rodents in these studies.
The mass of fed stomach contents per mouse and rat was esti-
mated to be 0.2 g and 1 g, respectively, based on measurements
from the full stomach adult female BALB/c mice (weighing 18–
22 g) and adult female Wistar rats (weighing 160–190 g) (McCon-
nell et al., 2008). These estimates are generally consistent with the
mass of stomach contents collected from each animal in our study,
and for mice, consistent with the mass of stomach contents re-
ported for male TO mice that were 6–8 weeks old, weighing 25–
30 g (Simpson and Peters, 1990). To estimate Cr(VI) loading to
the stomach contents, the drinking water intake per event, or bout,
was estimated based on species-speciﬁc measures of water inges-
tion per drinking bout from the published literature (Spector and
Smith, 1984; Ho and Chin, 1988; Glendinning and Smith, 1994).
Shown in Table 1, Cr(VI) stomach loading rates were calculated
based on Cr(VI) drinking water concentrations in the NTP (2008)
bioassay and our 90-d drinking water studies (Thompson et al.,
2011b,2012), estimated drinking water intake per bout, and the
mass of stomach contents in each rodent species. Using these in-
puts, the calculated Cr(VI) stomach loading concentrations ranged
from 0.1 to 180 mg Cr(VI) L1 of stomach contents in mice andTable 2
Study parameters used to measure Cr(VI) reduction in rodent stomach contents.
Study
parameter
Species Sample
incubation
time (min)
Volume of
stomach contents
used (mL)
Diluting
ﬂuid:
volume/type
Effect of
incubation
time
SD rat
(12 h-
fasted)
0, 30, 60, 90 0.5 4.5 mL 0.7%
HCl
Effect of
Cr(VI)
gastric
loading
B6C3F1
mice (fed)
60 0.3 2.7 mL H2O
deionized
Effect of
Cr(VI)
gastric
loading
Fischer
F344/N rats
(fed)
60 0.3 2.7 mL H2O
deionized
a Stomach contents in fed animals was of paste-like nature so the pH was approxima0.07–130 mg Cr(VI) L1 in rats, corresponding to drinking water
concentrations of 0.1–180 mg Cr(VI) L1 (Table 1).
Table 2 delineates the experimental conditions for each reduc-
tion study, including volume or mass of stomach contents used,
mass of Cr(VI) spike, ratio of stomach contents to dilution ﬂuid,
and pH measures. Spiking concentrations up to approximately
two times higher than the estimated loading concentrations were
tested to ensure that the relevant range of rates was evaluated.
2.3. Analytical methods: Hexavalent chromium quantitation by
speciated isotope dilution mass spectrometry (SIDMS)
SIDMS was used to quantify Cr(VI) and Cr(III) following spiking
of diluted stomach ﬂuids with known amounts of naturally abun-
dant Cr(VI) as SDD. This method was used because it allowed for
the measurement of Cr(VI) at precise times, within seconds of spik-
ing, and accounted for valence instability (reduction) that might
occur after sample collection (Huo et al., 1998; Rahman et al.,
2005; Nagourney et al., 2008). Additionally, SIDMS does not re-
quire an acidiﬁcation step, as do colorimetric methods, thus avoid-
ing any potential for bias due to changes in pH during analysis. The
analytical method, with minor modiﬁcations, is described in detail
elsewhere (Gürleyük and Wallschlager, 2001). In brief, a DionexDilution factor
(diluting ﬂuid:
stomach contents)
Stomach loading (mg
Cr(VI) L1 gastric
contents)
pH of ﬂuid
before
dilution a
pH of ﬂuid
after
dilution
9:1 2 NA 1
9:1 1, 15, 40, 152, 394 4 4.5
9:1 1, 21, 144 4 4.25–4.5
tely measured with a narrow range pH strip.
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was used with a Dionex anion exchange chromatography column
connected to a PerkinElmer Elan DRCII inductively coupled plas-
ma-mass spectrometer (Shelton, CT). All analyses were performed
in Dynamic Reaction Cell (DRC) mode, using ammonia as the reac-
tion gas, monitoring 50Cr, 52Cr and 53Cr. The chromatograms were
processed using Totalchrom software (PerkinElmer) to determine
the areas under the peaks for Cr(III) and Cr(VI) for all isotopes.
Chromium SIDMS Calculation Software (version 1 (973982)) pro-
vided by Applied Isotope Technologies was used to determine
the concentration of Cr(VI) and Cr(III) simultaneously in each sam-
ple. Pilot study work demonstrated that as Cr(VI) was reduced,
Cr(III) was generated (Supplemental Fig. 2).
All stomach content samples were prepared in 50 mL polypro-
pylene ﬂat bottom centrifuge tubes. Diluted stomach content sam-
ples were placed into a HotBlock system (Environmental Express,
Charleston, SC) and equilibrated at 37 C for 60 min. A PTFE encap-
sulated NdFeB stir magnet (Environmental Express) was placed
into each vial, and a StirBase (Environmental Express) was placed
under the Hotblock to achieve gentle mixing at 10 rpm. When an
aliquot of the digestion ﬂuid was transferred to the autosampler
vial, a known amount (at a ratio between 0.1 and 10 the Cr(VI)
concentration) of the enriched 53Cr(VI) and 50Cr(III) spike was
added immediately into the vial, and the vial was shaken and
placed in the autosampler for analysis. Each analysis by SIDMS
was conducted on duplicate aliquots of the spiked stomach sample
that was collected and enriched with rare isotopes at various time
points (i.e., 15 and 45 s; 1.5, 3, 5, 10, 20, and 60 min). SIDMS-mea-
sured results of the duplicate aliquot for each spiked stomach sam-
ple were averaged and presented herein.0.01 
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Fig. 1. Cr(VI) concentration vs. time curves following spiking with naturally
abundant Cr(VI) as SDD in stomach contents from (a) mice with initial spiking
concentrations of 394 (+), 152 (), 40 (), 15 (N), and 1 (j) mg Cr(VI) L1 stomach
contents, and (b) rats with initial spiking concentrations of 144 (), 21(), and 1 (j)
mg Cr(VI) L1 stomach contents. Symbols denote SIDMS-measured concentrations
with each point representing duplicate aliquots of the spiked stomach sample
quantiﬁed at various times (15 and 45 s; 1.5, 3, 5, 10, 20, and 60 min) and lines
present the ﬁt of the 2nd order model with second order rate constant k (0.2 and
0.3 L mg1 h1 for mice and rats, respectively) and capacities R of 16.6 and 15.7 mg
of Cr(VI)-equivalents per L stomach contents for mice and rats, respectively.
Adjusted R2 for rat and mouse models are 0.98 and 0.95, respectively. See text for
further discussion.2.4. Modeling
During pilot study investigations, initial attempts to describe
Cr(VI) concentration using a ﬁrst-order model were unsuccessful.
Instead, the concentrations of Cr(VI) in stomach contents were bet-
ter described using a mixed second-order model in which rate of
reduction was a function of both the concentration of Cr(VI) and
the concentration of reducing agent, [R] in the stomach. The rate
of change of Cr(VI) concentration in stomach contents was repre-
sented as:
dcjCrVIj
dt
¼ k½R½CrðVIÞ ð1Þ
This represents a mixed second-order reaction because the rate of
change depends on the concentration of Cr(VI) [Cr(VI)] as well as
the concentration of reducing agent [R], both of which are con-
sumed over the course of the reaction. The term, k, is the second-or-
der rate constant, expressed in terms of L stomach contents per mg
reducing equivalents per hour. In this model formulation, the
reducing agent was assumed to be consumed at the rate of 1 mg
R per mg Cr(VI) reacted; thus, the units for the reduction agent is
mg Cr(VI)-equivalents per liter of stomach contents. Identiﬁcation
of the actual stoichiometric mass and chemical identity of the
reducing agent(s), which likely include ascorbate, NADH, glutathi-
one, and other sulfhydryls, was outside the scope of this study.
However, this information is not necessary for the purposes of phar-
macokinetic modeling, and the surrogate units of mg of Cr(VI)-
equivalents are sufﬁcient. Estimates for the parameters k and R
were obtained for each species by adjusting their values to obtain
optimal ﬁts, as determined by the least squares method, to the
Cr(VI) concentration data from different starting concentrations of
Cr(VI). All modeling was performed in Microsoft Excel (version
14.1.3).3. Results
3.1. Cr(VI) reduction kinetics and modeling for rodent stomach
contents
Time-course data and modeled concentration vs. time curves
for Cr(VI) in mouse and rat stomach contents are presented in
Fig. 1a and b over ranges of starting concentrations from 1 to
approximately 400 mg Cr(VI) L1 stomach contents (Table 2). In
both rodent species, approximately 16 mg Cr(VI)-equivalents of
reducing agent per L of stomach contents was estimated by ﬁtting
the mixed second-order model. In mouse stomach contents, the
optimized model yielded a second-order rate constant, k, of
0.2 L mg1 h1 and a total reducing capacity (R0) of 16.6 mg
Cr(VI)-equivalents L1. In rat stomach contents, a k of
0.3 L mg1 h1, with a similar reducing capacity R0 of 15.7 mg
Cr(VI)-equivalents L1 stomach contents was determined. Only
three concentrations were tested in the rat stomach contents be-
cause it was evident that the model ﬁt the measured data after
the ﬁrst three concentrations were tested. Adjusted R-squared val-
ues (R2) for the rat and mouse models are 0.98 and 0.95,
respectively.
Fig. 2. Percent of Cr(VI) reduced within 60 min vs. initial loading of Cr(VI) in
stomach contents of mice and rats (mg Cr(VI) L1 stomach contents). Two replicate
measurements using SIDMS were taken at 60 min after initial loading. Results
presented herein are averages of each replicate.
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equivalents per L, the available reducing agents were consumed,
and the rate and extent of reduction was limited demonstrating
the second-order behavior. Data from the lowest spike concentra-
tion, 1 mg L1 of stomach contents, are also shown. The linear
behavior of the reduction curve at this lowest spike concentration
demonstrates the pseudo-ﬁrst-order behavior of the model at
Cr(VI) concentrations well below the initial concentration of reduc-
ing equivalents, R0, with an apparently linear rate constant equal to
the product of k and R0 in this concentration range. This corre-
sponds to the condition in which the reducing equivalents are
present at substantially greater concentrations than the added
Cr(VI). The non-linear behavior at higher concentrations demon-
strates the impact of the limited reduction capacity relative to
these spiking levels. The performance of the model over the range
of spiking levels in the mouse and rat experiments supports the
selection of this model as a reasonable structure for quantifying
reduction of Cr(VI) in rodent stomach contents.
The percent of Cr(VI) reduced within 60 min is presented in
Fig. 2. The fraction of Cr(VI) reduced within 60 min decreases with
increasing spike concentration, with nearly 100% reductionTable 3
Comparison of mouse and rat Cr(VI) stomach loading and reducing capacity.
Cr(VI) DW
concentrations
(mg L1)a
Water intake
per bout (L)a
Cr(VI) intake per
DW bout (mg)a
Cr(VI)- equivalent
reducing capacity
(mg mL1)b
St
on
Mouse
0.1 0.0002 0.00002 0.0166 0.
1.4 0.0002 0.00028 0.0166 0.
5.0 0.0002 0.0010 0.0166 0.
21 0.0002 0.0042 0.0166 0.
60 0.0002 0.012 0.0166 0.
180 0.0002 0.036 0.0166 0.
Rat
0.1 0.0007 0.00007 0.0157 1
1.4 0.0007 0.00098 0.0157 1
5.0 0.0007 0.00350 0.0157 1
21 0.0007 0.01470 0.0157 1
60 0.0007 0.04200 0.0157 1
180 0.0007 0.12740 0.0157 1
a See Table 1.
b Measured reduction capacity (see text) in mice and rats.
c Calculated as the product of the measured reduction capacity (0.0166 and 0.0157 m
times the species-speciﬁc stomach contents during fed states at any one time (see Tabl
d Calculated from Cr(VI) intake per drinking water bout (mg) and reducing equivalenoccurring at a spike concentration of 1 mg L1 of stomach contents.
At higher spiking concentrations, the percent of Cr(VI) reduced
within 60 min decreases, reﬂecting the reduction capacity limita-
tion of the stomach contents at these spiking levels.3.2. Evaluation of bioassay dose rates relative to Cr(VI) reduction
capacity
The data and models presented here allow comparison of the
Cr(VI) drinking water concentrations to the reducing capacity of
the rodent stomach. As noted earlier, reductive capacity in this
study refers to the mass of Cr(VI) reduced per volume of stomach
contents, given inﬁnite time to react. Because of the intermittent
nature of drinking water consumption and stomach emptying, esti-
mations of stomach reduction capacity were evaluated on the basis
of drinking water consumption events, which could be estimated
on an hourly basis for mice using the ﬁndings of Ho and Chin
(1988). Reduction capacity of stomach contents for an approximate
point in time under fed conditions (based on volume of stomach
contents and reducing capacity per L of stomach contents) is ex-
pected to be approximately 0.003 mg of Cr(VI)-equivalents in mice
and 0.016 mg in rats (Table 3). Comparing drinking water Cr(VI)
loading with reductive capacity suggests that reductive capacity
was exceeded at drinking water concentrations P21 mg L1 and
P60 mg L1 in mice and rats, respectively (Table 3).
It is important to consider that reductive capacities, as esti-
mated here, are static estimates used to inform the kinetics of
the dynamic stomach compartment, and simultaneously compet-
ing rates of stomach ﬂuid production, water and food intake, and
stomach emptying must be quantitatively assessed. In addition,
the reducing equivalents of the stomach content are regenerated
as more stomach ﬂuid is secreted, and additional Cr(VI) reduction
is expected to occur from the additional gastric ﬂuid production as
well as additional food consumption. Further, these reductive
capacity estimates are not intended to imply that at lower loading
rates of Cr(VI) to the stomach contents, which could be associated
with lower drinking water concentrations, Cr(VI) could not be
transported from the lumen of the stomach to the lumen of the
small intestine. Due to stomach emptying, Cr(VI) at lower drinking
water concentrations is also expected to be transferred to the lu-
men of the small intestine; however the concentration of Cr(VI)
entering the small intestine is not expected to be linear across doseomach contents at any
e time (fed state) (mL)a
Cr(VI) reducing
equivalents present
(mg)c
Cr(VI) intake per bout as a
percent of reducing capacityd
(%)
2 0.0033 0.6
2 0.0033 8.4
2 0.0033 30
2 0.0033 130
2 0.0033 360
2 0.0033 1100
0.0157 0.4
0.0157 7
0.0157 22
0.0157 94
0.0157 270
0.0157 810
g Cr(VI)-equivalents mL1 stomach content in mice and rats respectively; see text)
e 1).
t present at any one time (mg).
492 D.M. Proctor et al. / Chemosphere 89 (2012) 487–493due to the saturation of reduction capacity at the carcinogenic
doses. As such, PBTK models are needed to describe the simulta-
neously competing rates of the stomach compartment to estimate
target tissue dose in the small intestine at different drinking water
concentrations.4. Discussion
This is the ﬁrst study examining the reduction kinetics of Cr(VI)
in rodent stomach contents, and the ﬁrst study to measure rate of
reduction with measures of Cr(VI) collected at very short reaction
times (on the order of seconds to minutes). Generation of reduction
rate data in this timeframe is only possible using SIDMS, which ac-
counts for valence instability expected in a highly reducing sample,
such as stomach contents, during analysis.
These data demonstrate second-order reduction characteristics,
with a rate that is concentration-dependent and capacity limited.
Although reduction rates and capacities were similar between spe-
cies per L of stomach content, greater proportional reduction of
Cr(VI) occurs in rats as compared to mice at a given drinking water
concentration, resulting from lower loading of Cr(VI) in drinking
water per L of stomach contents in rats compared with mice (Ta-
ble 1). This observation is consistent with total Cr concentrations
in the duodenum of mice and rats following 90 d of drinking water
consumption, because concentrations in the mouse duodenum are
nearly twice as high as those in the rat duodenum at the highest
two drinking water concentrations (Thompson et al., 2011b,2012).
Each analysis by SIDMS was conducted on duplicate aliquots of
the spiked stomach sample that was collected and enriched with
rare isotopes at speciﬁed times, ranging from 15 s to 60 min after
spiking with SDD. Comparisons of SIDMS-measured Cr(VI) concen-
trations in the duplicate aliquots indicated that variability between
the duplicates was minimal and the calculated averages of the SID-
MS-measured Cr(VI) concentrations in duplicate samples were
generally within 10% of the range of the concentration measured
in each duplicate. Further, gastric ﬂuid collected from mice and
rats behaved similarly following second-order reduction kinetics,
with consistency in both Cr(VI) concentration and the concentra-
tion of reducing agents. Five Cr(VI) spiking concentrations in the
mice stomach content were evaluated, whereas only three spiking
concentrations were tested in the rat stomach contents because it
was evident that the K and r values ﬁt the measured data after the
ﬁrst three concentrations were tested.
Recent publications (Stout et al., 2009; Collins et al., 2010;
Stern, 2010) derived estimates of Cr(VI) gastric reduction capaci-
ties using BW3=4 scaling of post-prandial Cr(VI) reduction capacity
data in human gastric ﬂuids, as measured by De Flora et al.
(1997). Based on these calculations, the authors concluded that
reductive capacity was not saturated in mice at the NTP study
doses, except potentially in female mice at the highest adminis-
tered dose (Stout et al., 2009; Collins et al., 2010; Stern, 2010).
Although there are uncertainties in the reductive capacity mea-
sures developed herein and several possible reasons why these
measures may over- or underestimate reduction capacity for a gi-
ven set of conditions, these ex vivo data provide a basis for replac-
ing allometrically-scaled estimates of reductive capacity with
species-speciﬁc data.
For risk assessments and evaluating toxicokinetics, it is impor-
tant to consider that, due to the intermittent nature of drinking
water consumption and stomach emptying, time-dependent load-
ing relative to stomach content generation is expected to result in
intermittent exceedance of stomach reducing capacity. Thus, deliv-
ery of Cr(VI) to the small intestine may occur at concentrations be-
low the measures of reductive capacity presented in Table 3, and
such behavior will be modeled with the full PBTK model forrodents which is in development. Moreover, results are reported
here per L of stomach contents. However, experiments were con-
ducted in a reaction ﬂuid composed of stomach contents diluted
9:1 with DI water. Reduction rate model ﬁts to the observed data
provided equally good ﬁts whether the data were reported on a di-
luted or undiluted basis.
The observed Cr(VI) reduction behavior in rodent stomach con-
tents is concentration-dependent, second-order, and capacity-lim-
ited. The estimated Cr(VI) loading concentrations in rats and mice
exceeded the range of concentrations at which pseudo-linear
reduction behavior was observed at drinking water concentrations
of 21 and 5 mg/L, respectively. This is an important observation for
risk assessment because, as noted by (Zhitkovich, 2011), extrapo-
lating the rate of reduction across exposure concentrations may
be supported by a linear model if reduction occurs by pseudo
ﬁrst-order process at all relevant doses. Using measures of bio-
availability in humans at a wide range of exposures, Zhitkovich
(2011) estimated that 10–20% of ingested Cr(VI), regardless of con-
centration, is detoxiﬁed in the stomach. Based on this, Zhitkovich
(2011) concluded that it is reasonable to extrapolate the tumor re-
sponse data in mice of the NTP study to environmentally-relevant
human exposures. However, due to the concentration-dependence
and non-linearity of Cr(VI) reduction rate observed in these studies
at concentrations in the range of the recent rodent bioassays, the
use of a ﬁrst-order model to assess kinetics is not scientiﬁcally sup-
portable. Further, the stomach loading concentrations belowwhich
pseudo ﬁrst-order reduction rates occur in rodent stomach con-
tents is expected to be considerably different from that in humans
and comparable data for humans is needed for risk assessment.
5. Conclusions
Cr(VI) reduction in rodent stomach contents occurs by a mixed
second order rate which is capacity limited. These data are needed
for rodent-speciﬁc PBTK models that quantify competing loading,
reduction, absorption and stomach emptying rates and may be
used for evaluating target tissue dose from ingested Cr(VI) across
the range of interest for recent bioassays. Separate human- and ro-
dent-speciﬁc PBPK models, in combination with data regarding the
MOA, are needed for risk assessment and provide a more robust
scientiﬁc basis to extrapolate ﬁndings observed in laboratory ani-
mals to humans.
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